Veterinary Rabies Vaccines Market - By Animal Type (Companion [Dog, Cat], Livestock [Cattle, Sheep & Goat]), Application (Pre, Post- exposure Prophylaxis), Route of Administration (Oral, Injectable), End-use, Global Forecast (2024 – 2032)

Veterinary Rabies Vaccines Market Size

Veterinary Rabies Vaccines Market size was valued at USD 502.5 million in 2023 and is anticipated to grow at a CAGR of 4.2% between 2024 and 2032. The market is experiencing significant growth, driven primarily by the increasing prevalence of rabies in animals and the heightened awareness of its zoonotic nature. Rabies, a fatal viral disease, poses a substantial threat to both animal and human health, prompting governments and animal health organizations to intensify vaccination efforts. This has led to a surge in demand for rabies vaccines, especially in regions where the disease is endemic. 
 

Additionally, rising pet ownership rates globally have contributed to the market's expansion, as pet owners are becoming more conscious of the need to vaccinate their animals against rabies. The growing urbanization and expansion of livestock farming in developing countries are also fueling the demand for rabies vaccines as part of broader animal health management practices. Furthermore, supportive government policies and initiatives aimed at controlling rabies through mass vaccination campaigns are expected to sustain the market's growth trajectory in the coming years.
 

Veterinary rabies vaccines are crucial in preventing rabies, a fatal viral disease that affects the central nervous system of mammals, including humans and animals. These vaccines are primarily used to immunize domestic pets (such as dogs and cats), livestock, and wildlife against the rabies virus.
 

Veterinary Rabies Vaccines Market Trends

• Rising incidence of rabies is a key driver of the market. According to the World Organization of Animal Health (WOAH), rabies claims approximately 59,000 lives annually, with 99% of cases resulting from dog bites. This viral infection, which primarily affects mammals including domestic animals like dogs and cats, has an almost 100% fatality rate once clinical symptoms manifest. The alarming mortality rate has prompted global efforts to control and prevent rabies, leading to widespread vaccination programs.
   
• In 2023, the CDC reported that over one million dogs were vaccinated against rabies worldwide, and more than 25,000 rabid animals were investigated as part of control measures. This heightened awareness of rabies transmission from animals to humans, especially in regions with high stray animal populations and limited vaccine access, has driven a surge in demand for effective veterinary rabies vaccines.
   
• Governments and animal health organizations are also intensifying their vaccination campaigns, further propelling the market's growth. Consequently, the market is expected to expand, with increased investments in research and development to enhance vaccine efficacy and coverage.
   

Veterinary Rabies Vaccines Market Analysis

Based on the animal type, the market is categorized into companion animals, livestock animals, and wildlife. The companion animals’ segment is further classified into dogs, cats, and other companion animals. The companion animals segment dominated the market with USD 264.6 million in 2023.
 

• The growing awareness among pet owners about the importance of rabies vaccination, coupled with the increasing pet ownership rates globally, has significantly boosted the demand for rabies vaccines.
   
• Companion animals, particularly dogs and cats, are the primary reservoirs for rabies transmission to humans, making their vaccination a critical public health measure.
   
• Additionally, government regulations mandating rabies vaccination for pets in many countries have further contributed to the dominance of companion animals in this market.
   
• Further, the strong emotional bond between pet owners and their animals also drives a willingness to invest in preventive healthcare, including routine rabies vaccinations, ensuring the sustained high market share of this segment.
   

Based on application, the veterinary rabies vaccines market is segmented into pre-exposure prophylaxis and post-exposure prophylaxis. The post-exposure prophylaxis segment dominated the market holding the highest market share of 69.7% in 2023.
 

• The post-exposure prophylaxis (PEP) segment holds a significant market share in the market due to its critical role in preventing the onset of rabies following potential exposure.
   
• Veterinary PEP vaccines are vital in safeguarding animals, particularly domestic pets and livestock, which are at risk of rabies through contact with wild or infected animals.
   
• Additionally, the effectiveness of PEP in preventing the progression of rabies, which is almost always fatal once symptoms appear, further bolsters its demand and market dominance.
   

Based on route of administration, the veterinary rabies vaccines market is segmented into injectable and oral. The injectable segment is projected to reach USD 595.8 million by the end of 2032.
 

• The injectable segment holds a high market share in the market due to its proven efficacy, widespread acceptance among veterinarians, and the established safety profile of injectable formulations.
   
• These vaccines offer reliable immunogenicity and long-lasting protection, making them a preferred choice for rabies prevention in animals, particularly in regions with high rabies prevalence.
   
• Moreover, injectable rabies vaccines are easier to administer in a controlled environment, ensuring accurate dosing and reducing the risk of vaccine failure.
   
• The segment's dominance is further supported by the availability of various formulations tailored for different animal species, contributing to its broad market appeal.
   

Based on the end-use, the veterinary rabies vaccines market is segmented into veterinary hospitals & clinics, animal shelters & rescue organizations, and research institutes. The veterinary hospitals & clinics segment dominated the market in 2023 and is anticipated to witness growth at a CAGR of 4.1% between 2024 - 2032.
 

• Veterinary hospitals and clinics hold a significant market share in the market due to their central role in providing essential healthcare services for animals.
   
• These facilities are the primary points of contact for pet owners seeking preventive care, including vaccinations.
   
• The trust that pet owners place in veterinary professionals, combined with the comprehensive care offered by these hospitals and clinics, drives the demand for rabies vaccines in these settings.
   

In 2023, the North American veterinary rabies vaccines market was valued at USD 197.6 million and is projected to grow at a CAGR of 3.8% from 2024 to 2032.
 

• The region boasts a robust veterinary healthcare infrastructure, heightened awareness among pet owners, and stringent government regulations mandating rabies vaccinations for pets. 
   
• Moreover, the dominance of the market is bolstered by the presence of leading pharmaceutical companies and active research and development endeavors. 
   
• The combination of a high prevalence of rabies in wildlife and robust public health initiatives underscores the demand for veterinary rabies vaccines in North America, solidifying the region's global leadership.
   

In 2023, the U.S. veterinary rabies vaccines market was valued at USD 180 million.
 

• Data from the Centers for Disease Control & Prevention highlighted that in 2018, wild animals accounted for 92.7% of U.S. rabies cases. The most frequently reported rabid species included raccoons (30.3%), skunks (20.3%), foxes (7.2%), and bats (33%). This underscores the driving force behind the market's growth.
   
• Moreover, the U.S. benefits from a strong regulatory framework that guarantees high-quality vaccines and a well-established veterinary healthcare system that promotes widespread vaccine adoption. 
   
• Public awareness campaigns, coupled with stringent pet vaccination laws, bolster vaccination rates, cementing the U.S.'s leading role in the market.
   

The Asia Pacific region is set to experience notable growth, projected at a CAGR of 4.6% over the forecast period.
 

• Factors such as rapid urbanization and a surge in pet ownership are amplifying awareness and demand for animal health solutions, including rabies vaccines. 
   
• Countries like India and Indonesia grapple with a high prevalence of rabies, especially during common outbreaks, further fueling the demand.
   
• Government-led vaccination programs aimed at controlling rabies bolster market growth. 
   
• With advancements in vaccine technology and a growing veterinary healthcare infrastructure, the region is poised for significant market expansion. 
   
• These dynamics position the Asia Pacific as a pivotal player in the market.
   

India's veterinary rabies vaccines market is on the brink of substantial growth.
 

• In 2023, rabies remained a pressing public health issue in India, especially concerning dog bites. The nation is a significant player in the global rabies narrative, contributing to roughly 36% of worldwide rabies fatalities.
•  
• Dog bite incidents surged in 2023, with a 26.5% year-on-year increase, totaling approximately 2.75 million cases, up from 2.18 million in 2022. 
   
• Government initiatives, public health campaigns targeting rabies control, and advancements in vaccine technology are set to propel the market's growth in India.
   

Veterinary Rabies Vaccines Market Share

The competitive landscape of the market is characterized by a dynamic and rapidly evolving environment with several key players vying for market share. Leading pharmaceutical companies, such as Merck Animal Health, Zoetis, and Boehringer Ingelheim, dominate the market with their established portfolios of rabies vaccines and extensive distribution networks. These companies invest heavily in research and development to enhance vaccine efficacy, safety, and longevity.
 

The market is further shaped by strategic partnerships, mergers, and acquisitions aimed at expanding product offerings and geographic reach. Additionally, increasing awareness of rabies prevention in veterinary practice and rising government initiatives for animal health contribute to a competitive atmosphere where continuous innovation and cost-effective solutions are crucial for market success.
 

Veterinary Rabies Vaccines Market Companies

Few of the prominent players operating in veterinary rabies vaccines industry include:

• Biogénesis Bago S.A.
• Bioveta, a.s.
• Boehringer Ingelheim International GmbH
• Ceva Santé Animale S.A.
• Dyntec
• Elanco Animal Health Incorporated
• Indian Immunologicals Limited
• Merck & Co., Inc.
• Vaxxinova International B.V.
• Virbac S.A.
• Zoetis Inc.
   

Veterinary Rabies Vaccines Industry News:

• In June 2024, Merck Animal Health, a division of Merck & Co., Inc., announced the launch and availability of the NOBIVAC NXT Rabies portfolio – consisting of NOBIVAC NXT Feline-3 Rabies and NOBIVAC NXT Canine-3 Rabies – in Canada. The availability of these vaccines in Canada allows Merck to expand its market presence in North America, tapping into a new customer base and enhancing its competitive edge in the animal health sector.
   
• In June 2022, Ceva Santé Animale, a French multinational veterinary pharmaceutical company, acquired Artemis Technologies, Inc., a Canadian manufacturer specializing in oral rabies vaccines. This strategic acquisition was aimed at enhancing Ceva's portfolio in wildlife disease management, particularly in the North American market.
   

The veterinary rabies vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Animal Type

• Companion animals
  • Dogs
  • Cats
  • Other companion animals
• Livestock animals
  • Cattle
  • Sheep & goats
  • Other livestock animals
• Wildlife

Market, By Application

• Pre exposure prophylaxis
• Post exposure prophylaxis

Market, By Route of Administration

• Oral
• Injectable

Market, By End-use

• Veterinary hospitals & clinics
• Animal shelters & rescue organizations
• Research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa